Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
NEWS
Dr. Zheng Wei, Co-founder and CEO of Suzhou Connect Biopharma, Received Award of Taicang Innovation and Entrepreneurship Leading Talent

 

Suzhou Connect Biopharmaceuticals, Ltd. announced today that the companys co-founder and CEO Dr. Zheng Wei has been selected to receive the award of Taicang Innovation and Entrepreneurship Leading Talent. The award is given by Taicang Science and Technology Agency to outstanding entrepreneurs who establish companies in the Taicang city in the emerging industries in information technology, biology and medicine, new energy, high-end equipment manufacturing, new materials, environmental protection, alternative energy vehicles, as well as key areas of the service industry, agriculture, with projects, with technology. One of the award criteria is that the recipient must be principally responsible for the operation of the company and that the company must have built proprietary core technologies with strong commercialization potential. As part of the award, the company will receive research funding from the city to advance the companys R&D programs.
 
Media Contact: pr@connectpharm.com
 
About Suzhou Connect Biopharmaceuticals, Ltd.
Connect is a startup biopharmaceutical company dedicated to the discovery and development of novel therapeutics targeting G-protein coupled receptors (GPCR) for the treatment of autoimmune diseases, allergy and cancer. The company was founded by Dr. Zheng Wei, formerly Director of Immunology at Arena Pharmaceuticals, Inc., and Dr. William (Wubin) Pan, co-founder and formerly China President and Chief Operation Officer of Crown Biosciences, Inc., with investment from Xiang Tang Group. In addition to developing drug candidates through in-licensing, the company uses its proprietary GMab technology to discover and develop therapeutic antibodies against GPCR drug targets.

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.